Filing Flows › Gyre Therapeutics (GYRE) › Guidance & outlook
Gyre Therapeutics (GYRE) guidance and outlook
Gyre Therapeutics (GYRE) reaffirmed its guidance on Nov 5, 2026: Revenue $100M–$111M for FY2026. Gyre Therapeutics' 10-Q filed Nov 6, 2026 makes 21 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $100M–$111M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- As a result of the Cullgen acquisition, we intend to leverage Cullgen’s capabilities in the PRC for the development and early-stage clinical trials of various product candidates.
- F351 represents our primary liver-focused development program and reflects our commitment to advancing therapies targeting both viral- and metabolic-associated liver fibrosis.
- We are now planning a Phase 2 study to further evaluate CG001419 in cancer-induced bone pain (CIBP) or other metastatic cancer pain syndromes in China, which is expected to initiate in the first half of 2027.
- We anticipate Phase 1 dose-escalation data to be available in the second half of 2027.
- We plan to develop CG923308 for the treatment of solid tumors with CCNE1 amplification or HR+ / HER2- advanced breast cancer with resistance to current therapies.
- We intend to submit an IND application for CG923308 in the first quarter of 2027.
- We intend to submit an IND application for CG620953 in the United States or China around mid-2027.
- We are developing a robust suite of DACs that target both solid tumors and hematological malignancies by pairing distinct protein degraders with tumor-specific antibodies.
- F230 complements our broader organ-focused portfolio by expanding our development efforts into pulmonary vascular disease while remaining aligned with our strategy of targeting fibrotic and inflammatory pathways across organ systems.
- We anticipate submitting an IND application to the NMPA for F528 in 2026.
- We manage our research and development expenses by identifying the research and development activities we expect to be performed during a given period and then prioritizing efforts based on anticipated probability of successful technical development and regulatory approval, market potential, available human and capital resources, scientific data and other considerations.
- We regularly review our research and development activities based on unmet medical need and, as necessary, reallocate resources among our research and development portfolio that we believe will best support the long-term growth of our business.
Gyre Therapeutics' latest quarter
Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Gyre Therapeutics raise or lower its guidance?
Gyre Therapeutics (GYRE) reaffirmed its guidance on Nov 5, 2026: Revenue $100M–$111M for FY2026.
What does Gyre Therapeutics expect?
As a result of the Cullgen acquisition, we intend to leverage Cullgen’s capabilities in the PRC for the development and early-stage clinical trials of various product candidates. F351 represents our primary liver-focused development program and reflects our commitment to advancing therapies targeting both viral- and metabolic-associated liver fibrosis. We are now planning a Phase 2 study to further evaluate CG001419 in cancer-induced bone pain (CIBP) or other metastatic cancer pain syndromes in China, which is expected to initiate in the first half of 2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.